One of Achillion's several HCV compounds in development is ACH-2928, a potent NS5A inhibitor which Achillion discovered in 2009 and nominated as a clinical candidate in 2010. Because of the synergy noted in vitro between this NS5A inhibitor and NS3 protease inhibitors, Achillion has advanced ACH-2928 through preclinical development and completed IND-enabling studies for this compound. The Company expects to begin a Phase 1 first-in-man clinical trial evaluating ACH-2928 during 2011.
ACH-2928 Advantages:
Potency. ACH-2928 has demonstrated excellent potency against HCV RNA replication in all genotypes at concentrations ranging from 2 – 20pM.
Combinability. ACH-2928 is highly effective in combination with NS3 protease inhibitors, NS5B polymerase inhibitors, interferon and ribavirin. It is highly synergistic with Achillion's protease inhibitor, ACH-1625.
Specificity. ACH-2928 is highly specific for inhibition of NS5A protein with no inhibition of human proteins.
Pharmacokinetics. ACH-2928 is anticipated to be dosed once-daily without boosting.
Safety. ACH-2928 has demonstrated a good safety profile at high doses.
